Biolight's control-change deal collapsed, losses deepened, but new device approvals and BCI hype lifted shares
Control-change plan terminated, stock crashed The controlling shareholder's plan to sell control was called off, and when trading resumed the stock fell 20% in one day. Investors who had bought hoping for a buyout lost that hope, and the company remains without a new owner or fresh capital.
This is the single biggest new event of the period and directly explains the sharp price drop.
Interim loss widens, revenue and margins shrink The 2026 half-year report showed a net loss of 34.49 million yuan, swinging from profit to loss a year earlier. Revenue slipped 1.09%, gross margin fell to 22.86%, and debt rose, showing the core business is still struggling.
The weak financial results confirm the company's underlying problems and weigh on the stock.
New blood purification devices approved for sale Biolight received Class III medical device registration certificates for its Elix-Ω and Elix-90 blood purification devices, allowing them to be sold in China until 2031. This opens a new product line and potential future revenue.
This is a concrete positive regulatory step that could support future growth.
Brain-computer interface policy sparks 20% surge Zhejiang province issued measures to boost brain-computer interface technology, and Biolight's stock jumped 20% in afternoon trading as part of a sector rally. The move is sentiment-driven and may not reflect Biolight's own fundamentals.
This explains a sharp one-day price jump and shows how policy news can move the stock.